Stallergenes reports positive results for a p3 clinical study of allergic rhinitis in children
January 27, 2017Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, has reported positive topline results for a phase 3 clinical study of its sublingual immunotherapy tablet (STG320) for the treatment of house dust mite (HDM) induced allergic rhinitis in the pediatric population.
The trial, conducted in Japan by Stallergenes’s partner Shionogi & Co, showed good results, said the company in its press release on Friday. The results will be used to obtain Japan’s Pharmaceutical and Medical Device Agency’s approval.
Fereydoun Firouz, Chairman and CEO of Stallergenes Greer said that this data increases company’s understanding of STG320’s clinical profile and will enable it, in the future, to generate appropriate evidence packages which support registration in those markets where Actair can provide a valuable new therapeutic option.
In September 2010, Stallergenes SA signed exclusive partnership agreements with Shionogi & Co., Ltd. for the clinical development, registration and commercialization of sublingual house dust mite and Japanese cedar pollen immunotherapy tablets. As part of this, the Company is eligible for development, regulatory and sales milestones, as well as royalty payments on net sales.
